Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central anxious process, conolidine modulates alternate molecular targets. A Science Innovations study found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://ramseyf344amx1.evawiki.com/user